Recent market volatility may have many market participants buying major tech stocks on the dip , but the genuine opportunity may lie with blue chip stocks to buy on the dip. Blue-chips can be a great cornerstone for your portfolio. Representing ownership in venerable companies with consistent cash flow, blue chips typically experience steady price appreciation. Couple that with consistent dividends and dividend growth, and the total returns from such stocks can be quite solid. Yes, it’s not only market turbulence that has knocked down many blue chip stocks over the past few months. Company-specific factors have played a role as well. However, in many such cases, these headwinds are temporary and have become overly priced into shares. With this in mind, let’s dive in, and see why the following seven blue chip stocks to buy on the dip this month offer the opportunity to buy high-quality at a more-than-reasonable price. CVS Health (CVS) Source: Shutterstock CVS Health (NYSE: CVS ) is best known for its chain of pharmacies.

The last time I spoke about the top blue-chip stocks to buy on dips, I highlighted opportunity in the 2024 Dogs of the Dow . As I noted at the time , “Made up of the hardest-hit Dow stocks, which also pay out hefty dividend yields, you buy the Dogs at the start of the year, and cash out at the end of the year with hopeful wins in hand. In 2023, the Dogs of the Dow returned about 10.1%, as compared to the 14.4% gains on the overall Dow Jones Industrial Average . ” As for 2024 year to date, the top Dogs and the broader index have been a bit volatile. All thanks to incessant volatility, geopolitical tensions, and uncertainty over interest rate cuts. In fact, since the year began, the Dow Jones is up about 2%. Meanwhile, the Dogs are up an average of 5.3%, even more once you factor in dividends. While a good number of the Dogs have been performing well, others have some catching up to do after pulling back with the broader market. Here are three of the blue-chip stocks to buy on dips today.

In this piece, I evaluated two big pharma stocks, Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ), using TipRanks’ Comparison Tool below. A c…

In the changing environment of 2024, astute investors have a plethora of options to strengthen their financial portfolios strategically by purchasing dividend stocks . These prospects result from industry titans’ forward-thinking initiatives and solid performance. The top seven of them are listed here. For example, the first company distinguishes itself by spending substantial research and development to gain a competitive advantage in several therapeutic areas. Similarly, the second company’s substantial expenditures on fiber networks and 5G put it in the lead in the telecom market. Its solid cash flow and well-thought-out client retention tactics highlight the third company’s stability and resilience. In the meantime, the fourth company’s calculated acquisitions in the cancer and cardiovascular fields show that it is acutely aware of the need to capitalize on high-growth markets. Furthermore, the fifth company’s innovative strides in pharmacy operations and digital expansion, the sixth company’s successful return to market share, and the seventh company’s dominance in distribution paint a vivid picture of diverse opportunities across multiple industries.

Evotec reported financial results for fiscal year 2023, meeting updated guidance. The company announced a priority reset to focus on profitable growth, with adjustments expected to drive annualized EBITDA improvement over €40 million. Despite challenges, group revenues increased by 4% to €781.4 million, with Just - Evotec Biologics revenue up 111%. Adjusted Group EBITDA was €66.4 million. Strategic partnerships with Bristol Myers Squibb and Janssen, new collaborations, CEO transition, and approval of targets by SBTi were highlighted. Evotec plans to update mid-term forecast with H1 2024 results, expecting double-digit revenue growth and reduction in unpartnered R&D expenses. The company aims for sustainable and profitable growth, with a priority reset to streamline operations and enhance profitability.